A Agilent Technologies, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
A Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Diagnostics & Research
Current Price
Live
$135.05
Analyst Target
$169.67
+25.6%
Upside
52W High
$160.27
52W Low
$96.43
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$38.29B
P/E
30.28
ROE
20.6%
Profit margin
18.8%
Debt/Equity
0.53
Dividend yield
0.74%
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
Agilent Technologies exhibits strong fundamental health with a Piotroski F-Score of 8/9, indicating robust accounting strength, and solid profitability metrics including an ROE of 20.62% and operating margin of 26.38%. The company is growing revenue and earnings at double-digit rates, supported by consistent earnings beat rates and strong cash flow generation, though key financial data like Altman Z-Score and cash/debt figures are missing. However, the stock trades at a premium valuation (P/E of 30.28 vs sector average of 215 but with much lower growth than peers), and insider selling activity raises caution. While analysts are bullish with a $169.67 target price, the technical trend is bearish and recent price performance has been weak over the past year despite a short-term rebound.
Key Strengths
Exceptional Piotroski F-Score of 8/9 indicates high-quality financial statements and strong operational efficiency
High profitability with ROE above 20%, operating margin near 26.4%, and gross margin over 52%
Solid earnings growth momentum: YoY EPS growth of 24.5% and Q/Q growth of 23.6%
Consistent earnings beat record: 24 out of 25 quarters beating estimates, with frequent double-digit surprises
Low debt burden with Debt/Equity ratio of 0.53 and healthy liquidity (Current Ratio: 1.96)
Key Risks
Missing Altman Z-Score prevents full assessment of bankruptcy risk; potential red flag
Premium valuation: P/E of 30.28 exceeds forward P/E of 20.63 and may not fully reflect slowing growth
Bearish technical trend (0/100) and negative 1Y price return (-10.7%) suggest weak market sentiment
Insider selling activity: $3.34M in sales over last 6 months with no buys, including CEO transactions
Limited dividend appeal: low yield of 0.74% and weak Dividend Strength score of 25/100
AI Fair Value Estimate
Based on comprehensive analysis
$131.57
-2.6% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
71
Strong
60
82
88
85
40
AI Verdict
Moderately positive with caution due to valuation and insider activity
Key drivers: High Piotroski F-Score, Strong earnings growth and consistency, Premium valuation, Bearish technicals, Insider selling
Confidence
80%
Value
60/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 20.63 is reasonable for growth profile
- Intrinsic Value estimate of $131.57 close to current price
Watchpoints
- Current P/E of 30.28 is high relative to near-term growth
- Price/Sales and Price/Book ratios elevated at 5.51 and 5.67 respectively
Future
82/100
Ref Growth rates
Positives
- Revenue growth of 9.4% and earnings growth of 24.5% YoY
- Q/Q earnings growth remains strong at 23.6%
- Analyst target implies 25% upside
Watchpoints
No urgent risks highlighted.
Past
88/100
Ref Historical trends
Positives
- 24 out of 25 quarters beat EPS estimates
- Long history of positive earnings surprises averaging over 4% in recent years
- Stable and improving earnings trajectory since 2020
Watchpoints
No urgent risks highlighted.
Health
85/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 8/9 indicates excellent financial health
- Debt/Equity ratio of 0.53 shows conservative leverage
- Current and Quick Ratios above 1.4 indicate strong short-term liquidity
Watchpoints
- Altman Z-Score not available, limiting full solvency assessment
Dividend
40/100
Ref Yield, Payout
Positives
- Payout ratio of 21.71% is sustainable
Watchpoints
- Dividend yield of 0.74% is below market average
- Dividend Strength score very low at 25/100
- No data on dividend growth history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$135.05
Analyst Target
$169.67
Upside/Downside
+25.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for A and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
A
Agilent Technologies, Inc.
Primary
|
+11.4% | -11.3% | -10.7% | +12.8% | -2.2% | -3.3% |
|
ALC
Alcon Inc.
Peer
|
+8.8% | +9.9% | -9.6% | -12.6% | +0.1% | +1.6% |
|
ALNY
Alnylam Pharmaceuticals, Inc.
Peer
|
+98.7% | +48.5% | +17.9% | -25.2% | -22.3% | -2.9% |
|
HUM
Humana Inc.
Peer
|
-29.8% | -42.4% | +0.5% | +24.9% | +5.3% | -1.3% |
|
BNTX
BioNTech SE
Peer
|
+6.2% | -19.4% | -5.0% | +0.6% | +22.1% | +6.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
30.28
Forward P/E
20.63
PEG Ratio
N/A
P/B Ratio
5.67
P/S Ratio
5.51
EV/Revenue
5.76
EV/EBITDA
20.47
Market Cap
$38.29B
Profitability
Profit margins and return metrics
Profit Margin
18.75%
Operating Margin
26.38%
Gross Margin
52.43%
ROE
20.62%
ROA
8.48%
Growth
Revenue and earnings growth rates
Revenue Growth
+9.4%
Earnings Growth
+24.5%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+23.6%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.53
Moderate
Current Ratio
1.96
Good
Quick Ratio
1.44
Good
Cash/Share
$6.31
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-25
$N/A
2025-11-24
$1.59
+0.4% surprise
2025-08-27
$1.37
+0.2% surprise
2025-05-28
$1.31
+3.6% surprise
Healthcare Sector Comparison
Comparing A against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
P/E Ratio
30.28
This Stock
vs
197.75
Sector Avg
-84.7%
(Discount)
Return on Equity (ROE)
20.62%
This Stock
vs
-56.86%
Sector Avg
-136.3%
(Below Avg)
Profit Margin
18.75%
This Stock
vs
-20.8%
Sector Avg
-190.2%
(Weaker)
Debt to Equity
0.53
This Stock
vs
2.68
Sector Avg
-80.4%
(Less Debt)
Revenue Growth
9.4%
This Stock
vs
62.23%
Sector Avg
-84.9%
(Slower)
Current Ratio
1.96
This Stock
vs
3.45
Sector Avg
-43.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
A
Agilent Technologies, Inc.
|
NEUTRAL | $38.29B | 30.28 | 20.6% | 18.8% | $135.05 | |
|
ALC
Alcon Inc.
|
NEUTRAL | $39.59B | 38.6 | 4.8% | 10.3% | $80.29 | |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
BEARISH | $43.35B | 1093.87 | 32.7% | 1.4% | $328.16 | |
|
HUM
Humana Inc.
|
NEUTRAL | $32.87B | 25.59 | 7.2% | 1.0% | $273.28 | |
|
BNTX
BioNTech SE
|
NEUTRAL | $29.1B | - | -3.0% | -18.1% | $115.98 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-01 | DOLSTEN MIKAEL G | Director | Sale | 2,600 | $389,511 |
| 2025-11-26 | GONSALVES RODNEY | Officer | Sale | 3,000 | $464,956 |
| 2025-11-26 | GONSALVES RODNEY | Officer | Gift | 400 | $61,748 |
| 2025-11-18 | MCDONNELL PADRAIG | Chief Executive Officer | Sale | 911 | $130,492 |
| 2025-11-18 | MCDONNELL PADRAIG | Chief Executive Officer | Stock Award | 40,444 | - |
| 2025-11-18 | HENSON MEGHAN | Officer | Stock Award | 5,368 | - |
| 2025-11-18 | MAY SIMON | Officer | Stock Award | 6,781 | - |
| 2025-11-18 | RIEMANN ANGELICA | Officer | Stock Award | 8,274 | - |
| 2025-11-18 | KIRKWOOD JONAH PREVOST | Officer | Stock Award | 7,513 | - |
| 2025-11-18 | ZHANG JIANMIAO MIKE | Officer | Stock Award | 6,648 | - |
| 2025-11-18 | ELINOFF ADAM STEWART | Chief Financial Officer | Stock Award | 11,726 | - |
| 2025-11-18 | GONSALVES RODNEY | Officer | Stock Award | 4,942 | - |
| 2025-11-18 | DIMARCO BRET M | Officer | Stock Award | 6,922 | - |
| 2025-11-12 | MCDONNELL PADRAIG | Chief Executive Officer | Sale | 12,490 | $1,873,500 |
| 2025-11-12 | MCDONNELL PADRAIG | Chief Executive Officer | Option Exercise | 12,490 | $1,372,151 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
18 analysts
HSBC
2026-01-20
Buy
Evercore ISI Group
2026-01-05
In-Line
Outperform
Barclays
2025-12-15
Equal-Weight
Overweight
Goldman Sachs
2025-12-09
Buy
Morgan Stanley
2025-12-02
Overweight
Citigroup
2025-11-25
Buy
Buy
UBS
2025-11-25
Buy
Buy
Wells Fargo
2025-11-25
Overweight
Overweight
JP Morgan
2025-11-25
Overweight
Overweight
Barclays
2025-11-25
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning A from our newsroom.
Newest → oldest
No matching news yet.